Preclinical safety assessment of recombinant botulinum vaccine A/B (rBV A/B).

Authors:
Address: DynPort Vaccine Company LLC, A CSC Company, Frederick, MD 21702, USA. jshearer2@csc.com
Journal:

Publication:

abstract

A recombinant botulinum vaccine (rBV A/B) is being developed to protect adults 18-55 years of age from fatal botulism caused by inhalational intoxication with botulinum neurotoxin complex (BoNT) serotype A, subtype A1 (BoNT/A1) and BoNT serotype B, subtype B1 (BoNT/B1). Fundamental to the advanced development process is an initial demonstration of product safety in animals. A comprehensive series of studies was conducted to evaluate the general toxicity, neurobehavioral toxicity and local reactogenicity of the rBV A/B vaccine prior to first use in humans. Toxicity was evaluated in CD-1 mice vaccinated with control material and three dosages of rBV A/B with or without Alhydrogel(®) by intramuscular (IM) injection on Study Days 0, 28, 56 and 70 in a volume of 100μL. Total immunizing protein given in each dose was either 0, 2, 4 or 8 μg/animal. Local reactogenicity was evaluated in mice at the dosages given and in New Zealand white (NZW) rabbits using the same injection volume (0.5 mL) and formulations (10, 20 and 40 g/mL total antigen with 0.2% (w/v) Alhydrogel(®)) intended for human use. The rBV A/B vaccine produced no apparent systemic or neurobehavioral toxicity and only transient mild inflammation at the injection site. Together these results indicated a favorable safety profile for rBV A/B and supported its use in a Phase 1 clinical trial.

Related Articles
Botulinum neurotoxin neutralizing activity of immune globulin (IG) purified from clinical volunteers vaccinated with recombinant botulinum vaccine (rBV A/B).
Vaccine. 2010
Botulinum neurotoxin neutralizing activity of immune globulin (IG) purified from clinical volunteers vaccinated with recombinant botulinum vaccine (rBV A/B).
Shearer JD, Vassar ML, Swiderski W, Metcalfe K, Niemuth N, Henderson I. Vaccine. 2010 Oct 21; 28(45):7313-8. Epub 2010 Sep 1.
Inhalational botulism in rhesus macaques exposed to botulinum neurotoxin complex serotypes A1 and B1.
Clin Vaccine Immunol. 2010
Inhalational botulism in rhesus macaques exposed to botulinum neurotoxin complex serotypes A1 and B1.
Sanford DC, Barnewall RE, Vassar ML, Niemuth N, Metcalfe K, House RV, Henderson I, Shearer JD. Clin Vaccine Immunol. 2010 Sep; 17(9):1293-304. Epub 2010 Jul 21.
Final Report on Carcinogens Background Document for Formaldehyde.
Rep Carcinog Backgr Doc. 2010
Final Report on Carcinogens Background Document for Formaldehyde.
National Toxicology Program. Rep Carcinog Backgr Doc. 2010 Jan; (10-5981):i-512.
Review Botulinum neurotoxin vaccines: past, present, and future.
Crit Rev Immunol. 2007
Review Botulinum neurotoxin vaccines: past, present, and future.
Smith LA, Rusnak JM. Crit Rev Immunol. 2007; 27(4):303-18.
Review The science and manufacturing behind botulinum neurotoxin type A-ABO in clinical use.
Aesthet Surg J. 2009
Review The science and manufacturing behind botulinum neurotoxin type A-ABO in clinical use.
Wortzman MS, Pickett A. Aesthet Surg J. 2009 Nov; 29(6 Suppl):S34-42.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.